Collectively, the observation that the expression of CYP7B1 was significantly increased in AML patients suggests that pharmacological inhibition of CYP7B1 (expected to have an elevation of 27HC) would potentially have fewer long-term hematological side effects, particularly when used in combination with chemotherapy or radiation for the treatment of leukemia patients. Here, CYP7B1 is linked to leukemia.